SOPRANO: A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation Save

Date Added
October 24th, 2017
PRO Number
Pro00069319
Researcher
Brian Houston

Silhouette
Keywords
Cardiovascular
Summary

The purpose of this study is to evaluate the effect of an investigational study drug called macitentan, on the properties and function of the heart and on the blood pressure in the pulmonary arteries and to find out more about the safety of the study drug in subjects with pulmonary hypertension (PH) after left ventricular assist device (LVAD) implantation. The study will compare macitentan with a placebo to see if taking macitentan is better than taking a placebo

Institution
MUSC
Recruitment Contact
Kavin Panneerselvam
843-792-0464
panneeer@musc.edu

Hemodynamic Effects of Cardiac Resynchronization Therapy (CRT) on Subjects with Left Ventricular Assist Devices (LVADs) Save

Date Added
July 18th, 2017
PRO Number
Pro00067689
Researcher
Brian Houston

Silhouette
Keywords
Cardiovascular, Heart
Summary

For some patients with heart failure, we know that using a special pacemaker configuration called cardiac resynchronization therapy (CRT) can help them feel better and live longer. In fact, in these patients, we can see improvements in cardiac function with CRT as early as a few beats after we turn it on. However, some patients continue to be sick after CRT and ultimately require more help. Some of these patients will get a surgically implanted pump (called a left ventricular assist device, or LVAD) that does the work of their heart. We do not know if CRT continues to help (or may hurt) these patients. In this study, we will assess the effects of CRT in LVAD patients in the short term.

Institution
MUSC
Recruitment Contact
Brian Houston
843-876-4787
houstobr@musc.edu

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction Save

Date Added
June 13th, 2017
PRO Number
Pro00065900
Researcher
Brian Houston

Silhouette
Keywords
Cardiovascular
Summary

The purpose of this study is to find out more about how an investigational study drug called omecamtiv mecarbil, works in people with heart failure. Omecamtiv mecarbil is also known as AMG 423. Omecamtiv mecarbil is an investigational medicine that increases the heart's ability to pump. In this study, omecamtiv mecarbil will be compared to placebo.

Institution
MUSC
Recruitment Contact
Kavin Panneerselvam
843-792-0464
panneeer@musc.edu

Lymphangiogenesis Factors in Heart Failure States (LYFT-HF study) Save

Date Added
February 21st, 2017
PRO Number
Pro00062457
Researcher
Brian Houston

Silhouette
Keywords
Cardiovascular, Heart
Summary

Heart failure often causes fluid to accumulate in the body, leading to congestion and swelling. However, some people who have had heart failure for a long time seem to have very little congestion or swelling, even when the heart failure is poorly treated. We think that this is because lymphatic vessels are able to grow and remove fluid to prevent congestion. We do not know how lymphatic vessels grow. This study will investigate the blood levels of various proteins to see if we can figure out how the lymph vessels of people with long-standing heart failure might grow.

Institution
MUSC
Recruitment Contact
Renee Baxley
843-792-1105
baxleyr@musc.edu

Change_preferences

-- OR --

Create_login